Discussion about this post

User's avatar
Neural Foundry's avatar

Boston Scientific's continued wins in electrophysiology reflect Farapulse's market dominance. The scale advantage they've built with over 200,000 patients treated creates real barriers for competitors trying to enter PFA. Combining that EP success with their structural heart portfolio (especially WATCHMAN) gives them diversified growth engines in high margin cardiac segments. The broader neurotech roundup here is excellent, but Boston Scientific's electrophysiology momentm deserves special attention since they're effectivly defining the PFA market standards as the incumbent. J&J and Medtronic are responding defensively rather than dictating terms.

Expand full comment

No posts